Ceptaris Therapeutics Inc. is developing a proprietary gel formulation of mechlorethamine hydrochloride (mechlorethamine) for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of CTCL. Based upon results of a pivotal trial, Ceptaris submitted a new drug application (NDA) with the Food and Drug Administration (FDA) in 2011. If approved, Ceptaris’ investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 02/01/12 | Debt | 15M | Unknown |